Where I see patients (1)
Selected research
-
Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO resect group.
Neuro-oncology
-
Increasing growth and impact of Neuro-Oncology.
Neuro-oncology
-
Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival.
Neuro-oncology
Clinical trials
Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma
Signal-to-noise ratio (SNR) of HP 13C-aKG will be calculated voxel-by-voxel, and within each region of interest (ROI). The parameters considered will be the mean SNR, within these ROIs. Acquisition parameters will be optimized (su...
Recruiting
Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
Patients will be monitored for the occurrence of AEs that occur during the course of study participation. AE monitoring occurs on each day of hyperpolarized 13C pyruvate administration and until 7 days after administration. Seriou...
Recruiting
Hyperpolarized Imaging in Diagnosing Participants With Glioma
Adverse events will be monitored from just before investigational medicinal product (IMP) administration until the end of study participation. Vital signs (blood pressure and heart rate only) will be recorded at baseline and 30 mi...
Recruiting
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
Safety evaluation for endpoint will include monitoring for the occurrence of treatment-emergent adverse events (AEs). Reported toxicities will be graded using the National Cancer Institute (NCI) Common Terminology (Toxicity) Crite...
Recruiting
Contact me
- Request appointment
- Refer a patient
- (415) 353-2966